What You Should Know:
– Cytek Biosciences raises 120M in Series D funding –
underscoring the company’s growing momentum and significant contributions to
the field of cell analysis.
– Cytek, whose innovative flow cytometers represent the
first big technological leap in flow cytometry in decades, is currently
transitioning into a complete solution provider for the cell analysis market.
– This most recent funding round accelerates this transition and helps the company expand support for key areas of study including immunotherapy, immuno-oncology, and infectious diseases such as COVID-19.
Cytek Biosciences Inc., a Freemont, CA-based provider of cell analysis instrumentation and solutions, today announced that it has closed a $120 million Series D funding round, co-led by RA Capital and Hillhouse Capital, with OrbiMed and LYFE Capital also participating. The investment will be used to expand Cytek’s global infrastructure, sustain its growth momentum, and enable the company to deliver on its robust technology platform.
Reimagining Cell Analysis to Fuel Scientific Discovery
Founded in 1992, Cytek Biosciences Inc. is a leading flow
cytometry solution provider that develops compact, affordable instruments with
high multiplexing capability and a wide range of services to support scientists
and clinicians.
Representing the first big technological leap in flow cytometry in decades, Cytek’s cell analysis systems contain unique architectures that detect the full spectrum of the many fluorescent particles labeled on each cell. This technology enables the Cytek® Aurora to run beyond 40 color panels, a significant increase in the number of colors per sample, which in turn offers a much more complete picture of all the different cellular players in the immune system.
With the recent unveiling of a new
family of proprietary cFluor™ reagents, Cytek is transitioning into a
complete solution provider for the cell analysis market – inclusive of clinical
diagnostics. The company’s Series D funding round will help accelerate this
transition and offer expanded support for key areas of study such as
immunotherapy, immuno-oncology and infectious diseases such as COVID-19.
Additionally, RA Capital and Hillhouse Capital have joined Cytek’s board of directors. Said Andrew Levin, managing director of RA Capital, “The investments we make are evidence-based, and we are particularly focused on finding novel capabilities that address unsolved challenges. Cytek is ushering in flow cytometry’s next chapter with its proven, unique combination of innovative technologies. We are excited to join them on their mission to advance cancer and cell biology research.”
